Tscan Therapeutics Inc

NASDAQ:TCRX  
3.09
+0.07 (+2.32%)
Products

TScan Therapeutics Announces FDA Clearance Of Investigational New Drug Application For TSC-101

Published: 05/31/2022 12:00 GMT
Tscan Therapeutics Inc (TCRX) - Tscan Therapeutics Announces FDA Clearance of Investigational New Drug Application for Tsc-101 for the Treatment of Hematologic Malignancies.